kabutan

YOMEISHU SEIZO CO.,LTD.(2540) Summary

2540
TSE Prime
YOMEISHU SEIZO CO.,LTD.
4,015
JPY
-5
(-0.12%)
Apr 28, 3:30 pm JST
25.21
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
1.14
Yield
ー%
Margin Trading Ratio
38.77
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
4,020 JPY 25.22 USD
Previous Close Apr 27
4,020 JPY 25.21 USD
High Apr 28, 12:30 pm
4,025 JPY 25.29 USD
Low Apr 28, 3:30 pm
4,015 JPY 25.20 USD
Volume
343,600
Trading Value
1.38B JPY 8.67M USD
VWAP
4016.04 JPY 25.23 USD
Minimum Trading Value
401,500 JPY 2,521 USD
Market Cap
0.07T JPY 0.42B USD
Number of Trades
46
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
Mid
1-Year Average
155
1-Year High Dec 30, 2025
1,735
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 29,800
Apr 17, 2026 0 33,100
Apr 10, 2026 0 30,400
Apr 3, 2026 500 34,900 69.80
Mar 27, 2026 100 37,300 373.00
Company Profile
YOMEISHU SEIZO CO.,LTD. is the leading manufacturer of medicinal liquor, established in 1602. The company develops the "Yomeishu" brand. Its largest shareholder is Taisho Pharmaceutical.
Sector
Foods
YOMEISHU SEIZO CO.,LTD. primarily engages in the manufacturing and sales of "Yomeishu" and other alcoholic beverages and food products both domestically and internationally. Additionally, the company operates solar power generation for electricity sales, real estate leasing, and restaurant management. In the Yomeishu-related business, the company manufactures and sells alcoholic beverages and food products, including its flagship product "Yomeishu," in Japan and overseas. The company has also positioned its related businesses under the concept of "Expanding the Circle of Healthy Living," which it calls the "Kurasowa" business. This includes multi-faceted retail and service operations such as store management in directly-operated commercial facilities, restaurant management, mail-order sales, and external sales through other companies' distribution channels. YOMEISHU SEIZO CO.,LTD. is an equity-method affiliate of Taisho Pharmaceutical Holdings.